XSHE
002219
Market cap1.05bUSD
Oct 09, Last price
2.11CNY
1D
3.43%
1Q
6.57%
Jan 2017
-82.39%
IPO
6.82%
Name
New Journey Health Technology Group Co Ltd
Chart & performance
P/E
235.39
P/S
2.39
EPS
0.01
Div yield, %
—
Shrs. gr., 5y
12.03%
Rev. gr., 5y
0.24%
Revenues
3.05b
-19.64%
Net income
31m
-73.04%
CFO
294m
-33.00%
Dividend
Feb 28, 20140.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
This company maintains a diverse business portfolio, encompassing the provision of medical services, pharmaceutical manufacturing, and the distribution of daily chemical and wellness products. Its pharmaceutical production includes various dosage forms such as tablets, syrups, capsules, mixtures, and pills. The enterprise was established on September 30, 2001, with its primary office situated in Beijing, China.
Key people
Yanling Zhang
Vice Chairman of the Board · since 2023
Jun Liu
Chief Financial Officer · since 2023
Lihua Song
Senior Vice President, Director · since 2022
Chen Nie
Vice President · since 2022
Dian Zhu
Vice President · since 2023
Hengye Guan
Director · since 2022
Yanglin Lin
Chairman of the Board · since 2021
Minggui Xu
Director · since 2022
Ping Xue
Director · since 2024
Ziqing Zhou
Director · since 2022
Yiting Chi
Independent Director · since 2023
Jingmin Wang
Independent Director · since 2022
Bei Wang
Independent Director · since 2024
Xiaoqiang Xing
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||